Literature DB >> 33471029

Effectiveness of Systematic Echocardiographic Screening for Rheumatic Heart Disease in Nepalese Schoolchildren: A Cluster Randomized Clinical Trial.

Prahlad Karki1, Surendra Uranw1, Santosh Bastola1, Rajan Mahato1, Nikesh Raj Shrestha2, Kunjang Sherpa1, Sahadeb Dhungana3, Ayodele Odutayo4, Keshar Gurung2, Naveen Pandey1, Krishna Agrawal1, Prashant Shah1, Martina Rothenbühler5, Peter Jüni4, Thomas Pilgrim5.   

Abstract

Importance: Echocardiographic screening allows for early detection of subclinical stages of rheumatic heart disease among children in endemic regions. Objective: To investigate the effectiveness of systematic echocardiographic screening in combination with secondary antibiotic prophylaxis on the prevalence of rheumatic heart disease. Design, Setting, and Participants: This cluster randomized clinical trial included students 9 to 16 years of age attending public and private schools in urban and rural areas of the Sunsari district in Nepal that had been randomly selected on November 17, 2012. Echocardiographic follow-up was performed between January 7, 2016, and January 3, 2019. Interventions: In the experimental group, children underwent systematic echocardiographic screening followed by secondary antibiotic prophylaxis in case they had echocardiographic evidence of latent rheumatic heart disease. In the control group, children underwent no echocardiographic screening. Main Outcomes and Measures: Prevalence of the composite of definite or borderline rheumatic heart disease according to the World Heart Federation criteria in experimental and control schools as assessed 4 years after intervention.
Results: A total of 35 schools were randomized to the experimental group (n = 19) or the control group (n = 16). After a median of 4.3 years (interquartile range [IQR], 4.0-4.5 years), 17 of 19 schools in the experimental group (2648 children; median age at follow-up, 12.1 years; IQR, 10.3-12.5 years; 1308 [49.4%] male) and 15 of 16 schools in the control group (1325 children; median age at follow-up, 10.6 years; IQR, 10.0-12.5 years; 682 [51.5%] male) underwent echocardiographic follow-up. The prevalence of definite or borderline rheumatic heart disease was 10.8 per 1000 children (95% CI, 4.7-24.7) in the control group and 3.8 per 1000 children (95% CI, 1.5-9.8) in the experimental group (odds ratio, 0.34; 95% CI, 0.11-1.07; P = .06). The prevalence in the experimental group at baseline had been 12.9 per 1000 children (95% CI, 9.2-18.1). In the experimental group, the odds ratio of definite or borderline rheumatic heart disease at follow-up vs baseline was 0.29 (95% CI, 0.13-0.65; P = .008). Conclusions and Relevance: School-based echocardiographic screening in combination with secondary antibiotic prophylaxis in children with evidence of latent rheumatic heart disease may be an effective strategy to reduce the prevalence of definite or borderline rheumatic heart disease in endemic regions. Trial Registration: ClinicalTrials.gov Identifier: NCT01550068.

Entities:  

Mesh:

Year:  2021        PMID: 33471029      PMCID: PMC7818193          DOI: 10.1001/jamacardio.2020.7050

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  3 in total

1.  Investigation of the Familial Risk of Rheumatic Heart Disease with Systematic Echocardiographic Screening: Data from the PROVAR+ Family Study.

Authors:  Juliane Franco; Bruno R Nascimento; Andrea Z Beaton; Kaciane K B Oliveira; Marcia M Barbosa; Sanny Cristina C Faria; Nayana F Arantes; Luana A Mello; Maria Cecília L Nassif; Guilherme C Oliveira; Breno C Spolaor; Carolina F Campos; Victor R H Silva; Marcelo Augusto A Nogueira; Antonio L Ribeiro; Craig A Sable; Maria Carmo P Nunes
Journal:  Pathogens       Date:  2022-01-24

2.  Rheumatic heart disease in the heart of Himalayas.

Authors:  Saral Lamichhane; Nava Raj Sharma; Madalasa Pokhrel; Bishal Panthi; Manoj Bist
Journal:  Ann Med Surg (Lond)       Date:  2022-09-14

3.  Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study.

Authors:  Wubishet Belay; Azene Dessie; Hayat Ahmed; Etsegenet Gedlu; Abinet Mariyo; Abdulkadir Shehibo; Zemene Tigabu; Muktar H Aliyu; Jonathan Soslow
Journal:  BMC Cardiovasc Disord       Date:  2022-02-02       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.